Femasys FEMY
NASDAQ FEMY
$2.83 +0.15 (+5.60%)
At close: Sep 9, 2026 · 4:00 PM EDT

Femasys (FEMY) Net Income towards Common Stockholders (2020 - 2026)

Femasys' (FEMY) quarterly Net Income towards Common Stockholders came in at -$4.5 million in Q2 2026, up 2.55% on a YoY basis from -$4.4 million in Q2 2025, and up 2.55% quarter-over-quarter from -$4.6 million in Q2 2025.

Analysis

Femasys (FEMY) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends

Femasys (FEMY) has reported Net Income towards Common Stockholders for 7 consecutive years, with -$4.5 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Net Income towards Common Stockholders rose 2.55% year-over-year to -$4.5 million; the trailing twelve-month figure through Jun 2026 stood at -$20.1 million (up 4.47% YoY), and the FY2025 full-year result was -$18.6 million, up 1.0% from the prior year.
  • Net Income towards Common Stockholders grew to -$4.5 million in Q2 2026 per FEMY's latest filing, from -$4.6 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at -$2.6 million in Q2 2022 and bottomed at -$5.9 million in Q1 2025.
  • Historically, Net Income towards Common Stockholders has averaged -$4.0 million across 5 years, with a median of -$4.0 million in 2023.
  • The sharpest annual moves came in 2022 and 2026: Net Income towards Common Stockholders plunged 143.21% in 2022, then increased 2.55% in 2026.
  • Over 5 years, Net Income towards Common Stockholders stood at -$2.9 million in 2022, then tumbled by 52.39% to -$4.4 million in 2023, then fell by 16.17% to -$5.1 million in 2024, then rose by 10.5% to -$4.6 million in 2025, then gained by 2.55% to -$4.5 million in 2026.
  • According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$4.5 million, -$4.6 million, and -$5.9 million for Q2 2026, Q2 2025, and Q1 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Abbott Laboratories 183.04 Bn 177.44 Bn 7.27 Bn 928.00 Mn
2 Intuitive Surgical 125.02 Bn 119.81 Bn 1.96 Bn 823.20 Mn
3 Medtronic 117.84 Bn 109.02 Bn 6.34 Bn 1.48 Bn
4 Stryker 105.50 Bn 102.02 Bn 4.50 Bn 1.28 Bn
5 Boston Scientific 66.27 Bn 65.73 Bn 3.85 Bn 907.00 Mn
6 Edwards Lifesciences 49.60 Bn 45.35 Bn 1.35 Bn 241.40 Mn
7 Alcon 33.70 Bn 32.24 Bn 1.68 Bn -
8 Dexcom 32.06 Bn 30.11 Bn 830.00 Mn 249.10 Mn
9 Steris 21.02 Bn 20.54 Bn 684.20 Mn 201.00 Mn
10 Femasys 9.37 Mn 7.92 Mn 189,391.00 -4.47 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -4.47 Mn
Jun 30, 2025 -4.59 Mn
Mar 31, 2025 -5.90 Mn
Dec 31, 2024 -5.12 Mn
Sep 30, 2024 -5.41 Mn
Jun 30, 2024 -4.68 Mn
Mar 31, 2024 -3.60 Mn
Dec 31, 2023 -4.41 Mn
Sep 30, 2023 -4.00 Mn
Jun 30, 2023 -2.89 Mn
Mar 31, 2023 -2.95 Mn
Dec 31, 2022 -2.89 Mn
Sep 30, 2022 -2.98 Mn
Jun 30, 2022 -2.63 Mn
Mar 31, 2022 -2.88 Mn
Dec 31, 2021 -2.36 Mn
Sep 30, 2021 -2.26 Mn
Jun 30, 2021 -1.08 Mn
Mar 31, 2021 -1.83 Mn
Dec 31, 2020 -1.66 Mn